Symbols / PRTC Stock $18.14 +2.63% PureTech Health plc

Healthcare • Biotechnology • United States • NGM
PRTC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Robert Lyne J.D., L.L.B.
Exch · Country NGM · United States
Market Cap 441.56M
Enterprise Value 4.18B
Income 50.68M
Sales 6.39M
FCF (ttm) -160.19M
Book/sh 15.65
Cash/sh 1.38
Employees 56
Insider 10d —
IPO Nov 16, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 10.67
Forward P/E -36.28
PEG —
P/S 69.09
P/B 1.16
P/C —
EV/EBITDA -36.15
EV/Sales 654.60
Quick Ratio 8.35
Current Ratio 8.49
Debt/Eq 44.33
LT Debt/Eq —
EPS (ttm) 1.70
EPS next Y -0.50
EPS Growth —
Revenue Growth 5.43%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-29
Earnings (prior) —
ROA -12.95%
ROE 9.44%
ROIC —
Gross Margin 0.00%
Oper. Margin -25.90%
Profit Margin 7.93%
Shs Outstand 24.34M
Shs Float 167.37M
Insider Own 0.00%
Instit Own 0.39%
Short Float 0.08%
Short Ratio 3.78
Short Interest 15.35K
52W High 19.92
vs 52W High -8.94%
52W Low 14.50
vs 52W Low 25.10%
Beta 0.71
Impl. Vol. —
Rel Volume 3.83
Avg Volume 4.03K
Volume 15.42K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $17.68
Price $18.14
Change 2.63%
About

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$18.14
Latest analyst target
3. DCF / Fair value
$-118.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.14
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2022-08-25 main Piper Sandler — → Overweight $44
2022-08-09 main SVB Leerink — → Outperform $70
2022-06-15 main SVB Leerink — → Outperform $66
2022-01-07 main SVB Leerink — → Outperform $70
2021-08-25 main SVB Leerink — → Outperform $76
2021-01-15 init SVB Leerink — → Outperform $70
News
RSS: Latest PRTC news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
4.32
+475.33%
0.75
-64.11%
2.09
-79.06%
9.98
Operating Revenue
4.32
+475.33%
0.75
-64.11%
2.09
-79.06%
9.98
Operating Expense
140.41
-4.45%
146.95
-26.49%
199.90
+24.73%
160.26
Research And Development
54.28
-26.38%
73.73
-33.75%
111.29
+42.16%
78.28
Selling General And Administration
27.49
+9.18%
25.18
-20.32%
31.60
+18.29%
26.71
General And Administrative Expense
27.49
+9.18%
25.18
-20.32%
31.60
+18.29%
26.71
Other Operating Expenses
3.70
-11.70%
4.19
-19.35%
5.19
+11.77%
4.65
Total Expenses
140.41
-4.45%
146.95
-26.49%
199.90
+24.73%
160.26
Operating Income
-136.09
+6.91%
-146.20
+26.09%
-197.81
-31.62%
-150.28
Total Operating Income As Reported
-136.09
+6.91%
-146.20
+26.09%
-197.81
-31.62%
-150.28
EBITDA
37.38
+311.42%
-17.68
+77.88%
-79.94
-70.25%
-46.95
Normalized EBITDA
-104.54
+34.64%
-159.94
+21.10%
-202.72
+5.69%
-214.95
Reconciled Depreciation
3.57
-27.61%
4.93
-44.53%
8.89
+22.04%
7.29
EBIT
33.81
+249.51%
-22.61
+74.54%
-88.83
-63.78%
-54.24
Total Unusual Items
141.93
-0.24%
142.26
+15.86%
122.78
-26.91%
168.00
Total Unusual Items Excluding Goodwill
141.93
-0.24%
142.26
+15.86%
122.78
-26.91%
168.00
Special Income Charges
152.28
+146.46%
61.79
+31.24%
47.08
0.00
Other Special Charges
-152.28
-146.46%
-61.79
-11.39%
-55.47
-104762.26%
0.05
Impairment Of Capital Assets
—
—
—
0.00
Write Off
0.00
0.00
-100.00%
8.39
0.00
Net Income
53.51
+181.45%
-65.70
-30.47%
-50.35
+16.85%
-60.56
Pretax Income
23.77
+165.85%
-36.10
+61.09%
-92.78
-57.38%
-58.95
Net Non Operating Interest Income Expense
12.63
+400.48%
2.52
+36.73%
1.85
+141.02%
-4.50
Interest Expense Non Operating
10.04
-25.59%
13.49
+241.21%
3.95
-16.14%
4.71
Net Interest Income
12.63
+400.48%
2.52
+36.73%
1.85
+141.02%
-4.50
Interest Expense
10.04
-25.59%
13.49
+241.21%
3.95
-16.14%
4.71
Interest Income Non Operating
22.67
+41.58%
16.01
+176.12%
5.80
+2609.81%
0.21
Interest Income
22.67
+41.58%
16.01
+176.12%
5.80
+2609.81%
0.21
Other Non Operating Income Expenses
0.96
+205.84%
-0.91
-111.17%
8.13
+410.74%
1.59
Tax Provision
-4.01
-113.13%
30.52
+154.78%
-55.72
-1583.47%
3.76
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
-22.22%
0.00
Tax Effect Of Unusual Items
29.80
-0.24%
29.87
+15.86%
25.78
-43.16%
45.36
Net Income Including Noncontrolling Interests
27.78
+141.70%
-66.63
-79.76%
-37.06
+40.89%
-62.71
Net Income From Continuing Operation Net Minority Interest
53.51
+181.45%
-65.70
-30.47%
-50.35
+16.85%
-60.56
Net Income From Continuing And Discontinued Operation
53.51
+181.45%
-65.70
-30.47%
-50.35
+16.85%
-60.56
Net Income Continuous Operations
27.78
+141.70%
-66.63
-79.76%
-37.06
+40.89%
-62.71
Minority Interests
25.73
+2663.48%
0.93
+107.01%
-13.29
-717.85%
2.15
Normalized Income
-58.61
+67.09%
-178.08
-20.86%
-147.35
+19.57%
-183.20
Net Income Common Stockholders
53.51
+181.45%
-65.70
-30.47%
-50.35
+16.85%
-60.56
Otherunder Preferred Stock Dividend
0.00
0.00
0.00
0.00
Diluted EPS
2.10
+187.50%
-2.40
-33.33%
-1.80
+14.29%
-2.10
Basic EPS
2.10
+187.50%
-2.40
-33.33%
-1.80
+14.29%
-2.10
Basic Average Shares
25.45
-7.91%
27.63
-2.97%
28.48
-0.64%
28.66
Diluted Average Shares
25.60
-7.34%
27.63
-2.97%
28.48
-0.64%
28.66
Diluted NI Availto Com Stockholders
53.51
+181.45%
-65.70
-30.47%
-50.35
+16.85%
-60.56
Amortization
1.76
-10.86%
1.98
-35.07%
3.05
+3.67%
2.94
Depreciation And Amortization In Income Statement
3.57
-27.62%
4.93
-44.52%
8.89
+22.04%
7.29
Depreciation Income Statement
1.81
-38.85%
2.96
-49.44%
5.84
+34.46%
4.35
Line Item Trend 2024-12-31 2023-12-31 2022-12-31
Total Assets
602.63
-13.16%
693.97
-1.23%
702.65
Current Assets
386.26
+11.25%
347.20
-10.10%
386.19
Cash Cash Equivalents And Short Term Investments
367.31
+12.28%
327.14
-6.56%
350.10
Cash And Cash Equivalents
280.64
+46.87%
191.08
+27.50%
149.87
Other Short Term Investments
86.67
-36.30%
136.06
-32.05%
200.23
Accounts Receivable
1.52
-35.94%
2.38
-79.98%
11.87
Other Receivables
11.38
—
—
Taxes Receivable
0.00
-100.00%
11.75
+16.99%
10.04
Prepaid Assets
4.40
+2.20%
4.31
-62.91%
11.62
Restricted Cash
1.64
+0.86%
1.63
-23.35%
2.12
Other Current Assets
—
-0.00
+0.00%
-0.00
Total Non Current Assets
216.38
-37.60%
346.77
+9.58%
316.45
Net PPE
15.13
-21.86%
19.36
-48.01%
37.24
Gross PPE
27.98
-13.50%
32.34
-43.57%
57.32
Accumulated Depreciation
-12.85
+1.04%
-12.98
+35.35%
-20.08
Properties
0.00
0.00
0.00
Buildings And Improvements
15.16
+0.00%
15.16
-36.72%
23.96
Machinery Furniture Equipment
1.60
-19.46%
1.99
-32.09%
2.93
Construction In Progress
0.00
-100.00%
0.00
-99.96%
2.80
Other Properties
11.21
-26.20%
15.19
-45.01%
27.62
Goodwill And Other Intangible Assets
0.60
-33.66%
0.91
+9.03%
0.83
Other Intangible Assets
0.60
-33.66%
0.91
+9.03%
0.83
Long Term Equity Investment
2.40
-24.74%
3.19
-65.18%
9.15
Other Non Current Assets
0.48
-45.79%
0.88
+8680.00%
0.01
Total Liabilities Net Minority Interest
194.70
-17.41%
235.74
+52.03%
155.06
Current Liabilities
41.39
-19.43%
51.37
-46.98%
96.89
Payables
6.51
-55.51%
14.64
-48.66%
28.52
Accounts Payable
5.52
-62.27%
14.64
-44.77%
26.50
Other Payable
0.92
+30466.67%
0.00
-99.85%
1.96
Pensionand Other Post Retirement Benefit Plans Current
1.88
+46.37%
1.28
-29.03%
1.80
Total Tax Payable
0.07
0.00
-100.00%
0.06
Current Debt And Capital Lease Obligation
7.69
+8.42%
7.09
-43.13%
12.47
Current Debt
4.11
+11.14%
3.70
-50.69%
7.50
Current Capital Lease Obligation
3.58
+5.45%
3.39
-31.74%
4.97
Other Current Liabilities
6.60
+3807.69%
0.17
-99.38%
27.34
Total Non Current Liabilities Net Minority Interest
153.31
-16.85%
184.37
+216.94%
58.17
Long Term Debt And Capital Lease Obligation
14.67
-19.61%
18.25
-46.95%
34.40
Long Term Debt
—
0.00
-100.00%
10.24
Long Term Capital Lease Obligation
14.67
-19.61%
18.25
-24.45%
24.16
Non Current Pension And Other Postretirement Benefit Plans
1.86
-46.84%
3.50
-15.19%
4.13
Non Current Deferred Taxes Liabilities
0.00
-100.00%
52.46
+167.05%
19.64
Other Non Current Liabilities
136.78
+24.17%
110.16
+11015800.00%
0.00
Stockholders Equity
414.71
-10.64%
464.07
-14.41%
542.22
Common Stock Equity
414.71
-10.64%
464.07
-14.41%
542.22
Capital Stock
4.86
-11.01%
5.46
+0.11%
5.46
Common Stock
4.86
-11.01%
5.46
+0.11%
5.46
Share Issued
257.93
-10.90%
289.47
+0.11%
289.16
Ordinary Shares Number
239.42
-11.93%
271.85
-2.41%
278.57
Treasury Shares Number
18.51
+5.06%
17.61
+66.25%
10.60
Additional Paid In Capital
290.26
+0.00%
290.26
+0.22%
289.62
Retained Earnings
32.49
-61.24%
83.82
-43.94%
149.52
Treasury Stock
46.86
+5.02%
44.63
+68.45%
26.49
Minority Interest
-6.77
-16.09%
-5.83
-208.68%
5.37
Total Equity Gross Minority Interest
407.93
-10.98%
458.23
-16.32%
547.59
Total Capitalization
414.71
-10.64%
464.07
-16.00%
552.46
Working Capital
344.87
+16.58%
295.83
+2.26%
289.31
Invested Capital
418.82
-10.46%
467.76
-16.47%
559.97
Total Debt
22.36
-11.77%
25.34
-45.93%
46.87
Capital Lease Obligations
18.25
-15.68%
21.64
-25.69%
29.13
Net Tangible Assets
414.11
-10.59%
463.16
-14.45%
541.39
Tangible Book Value
414.11
-10.59%
463.16
-14.45%
541.39
Available For Sale Securities
191.43
-39.77%
317.84
+26.18%
251.89
Financial Assets Designatedas Fair Value Through Profitor Loss Total
191.43
-39.77%
317.84
+26.18%
251.89
Investmentin Financial Assets
191.43
-39.77%
317.84
+26.18%
251.89
Investmentsin Associatesat Cost
2.40
-24.74%
3.19
-65.18%
9.15
Other Equity Interest
0.00
+200.00%
-0.00
—
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-134.37
-26.86%
-105.92
+40.76%
-178.79
-12.96%
-158.27
Net Income From Continuing Operations
27.78
+141.70%
-66.63
-79.76%
-37.06
+40.89%
-62.71
Depreciation
1.81
-38.83%
2.95
-66.78%
8.89
+104.58%
4.35
Amortization Cash Flow
1.76
-10.86%
1.98
-35.07%
3.05
+3.67%
2.94
Depreciation And Amortization
3.57
-27.61%
4.93
-44.53%
8.89
+22.04%
7.29
Other Non Cash Items
-12.63
-400.48%
-2.52
-36.73%
-1.85
-141.02%
4.50
Stock Based Compensation
22.85
+417.55%
4.42
-69.96%
14.70
+5.36%
13.95
Deferred Tax
-4.01
-113.13%
30.52
+154.78%
-55.72
-1583.47%
3.76
Gain Loss On Investment Securities
-2.76
+94.73%
-52.38
+37.44%
-83.72
+50.38%
-168.74
Net Foreign Currency Exchange Gain Loss
0.03
-73.40%
0.09
+771.43%
-0.01
-125.00%
0.06
Gain Loss On Sale Of PPE
—
—
0.14
+160.38%
0.05
Change In Working Capital
-10.24
-158.43%
17.52
+10.05%
15.92
+1748.90%
0.86
Change In Receivables
0.63
-93.55%
9.75
+226.07%
-7.73
-1153.48%
-0.62
Change In Prepaid Assets
-1.26
-144.53%
2.83
+428.77%
-0.86
+83.89%
-5.35
Change In Payable
-9.70
-352.21%
3.84
-82.55%
22.03
+164.25%
8.34
Change In Other Current Assets
0.09
-91.57%
1.09
-56.04%
2.48
+264.37%
-1.51
Change In Other Current Liabilities
—
—
—
0.00
Investing Cash Flow
240.89
+249.16%
68.99
+164.34%
-107.22
-154.32%
197.38
Net PPE Purchase And Sale
0.24
-69.31%
0.80
+136.53%
-2.18
+60.73%
-5.54
Purchase Of PPE
-0.01
+84.29%
-0.07
+96.78%
-2.18
+60.94%
-5.57
Sale Of PPE
0.26
-70.52%
0.86
0.00
-100.00%
0.03
Capital Expenditure
-0.01
+95.51%
-0.24
+88.74%
-2.18
+61.56%
-5.66
Net Investment Purchase And Sale
346.61
+321.90%
82.16
+196.63%
-85.02
-141.96%
202.62
Purchase Of Investment
-309.60
-58.19%
-195.71
+27.17%
-268.73
-1633.76%
-15.50
Sale Of Investment
656.22
+136.16%
277.87
+51.25%
183.71
-15.78%
218.12
Net Business Purchase And Sale
-105.97
-668.79%
-13.78
+32.56%
-20.44
0.00
Purchase Of Business
-105.97
-668.79%
-13.78
+32.56%
-20.44
0.00
Gain Loss On Sale Of Business
-152.01
-146.02%
-61.79
-11.39%
-55.47
0.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.17
0.00
+100.00%
-0.09
Purchase Of Intangibles
0.00
+100.00%
-0.17
0.00
+100.00%
-0.09
Net Other Investing Changes
—
—
0.42
+9.19%
0.38
Financing Cash Flow
-16.96
-121.70%
78.14
+361.98%
-29.83
-231.24%
22.73
Net Issuance Payments Of Debt
0.00
0.00
-100.00%
0.39
-82.26%
2.21
Issuance Of Debt
0.00
0.00
-100.00%
0.39
-82.26%
2.21
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
0.00
0.00
-100.00%
0.39
-82.26%
2.21
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
0.00
0.00
-100.00%
0.39
-82.26%
2.21
Short Term Debt Issuance
—
0.00
-100.00%
0.39
-82.26%
2.21
Net Short Term Debt Issuance
—
0.00
-100.00%
0.39
-82.26%
2.21
Net Common Stock Issuance
-106.66
-476.66%
-18.50
+29.29%
-26.16
-101.56%
-12.98
Common Stock Payments
-107.56
-447.37%
-19.65
+25.83%
-26.49
0.00
Repurchase Of Capital Stock
-107.56
-447.37%
-19.65
+25.83%
-26.49
0.00
Net Other Financing Charges
93.10
-6.88%
99.98
+285745.71%
-0.04
-100.09%
36.87
Changes In Cash
89.56
+117.30%
41.22
+113.05%
-315.84
-610.84%
61.83
Effect Of Exchange Rate Changes
—
—
—
0.00
Beginning Cash Position
191.08
+27.50%
149.87
-67.82%
465.71
+15.31%
403.88
End Cash Position
280.64
+46.87%
191.08
+27.50%
149.87
-67.82%
465.71
Free Cash Flow
-134.38
-26.58%
-106.16
+41.34%
-180.97
-10.39%
-163.94
Common Stock Issuance
0.90
-22.38%
1.15
+247.29%
0.33
+102.56%
-12.98
Interest Paid CFO
-1.29
+23.87%
-1.70
+49.47%
-3.37
+0.47%
-3.38
Interest Received CFO
23.55
+62.91%
14.45
+317.75%
3.46
+1516.82%
0.21
Issuance Of Capital Stock
0.90
-22.38%
1.15
+247.29%
0.33
+102.56%
-12.98
Other Cash Adjustment Outside Changein Cash
-0.00
—
—
-0.00
Taxes Refund Paid
-37.91
-25175.33%
-0.15
+99.28%
-20.70
+25.46%
-27.77
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category